The stock of VolitionRX Ltd (NYSEMKT:VNRX) is a huge mover today! The stock decreased 4.33% or $0.24 on September 30, hitting $5.3. About 292,358 shares traded hands or 321.09% up from the average. VolitionRX Ltd (NYSEMKT:VNRX) has risen 44.81% since February 29, 2016 and is uptrending. It has outperformed by 34.38% the S&P500.
The move comes after 5 months negative chart setup for the $123.33M company. It was reported on Oct, 1 by Barchart.com. We have $4.66 PT which if reached, will make NYSEMKT:VNRX worth $14.80M less.
Analysts await VolitionRX Ltd (NYSEMKT:VNRX) to report earnings on November, 2. They expect $-0.13 earnings per share, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.13 actual earnings per share reported by VolitionRX Ltd for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company’s development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.”
Insitutional Activity: The institutional sentiment is 3.5 in Q2 2016. Its the same as in 2016Q1. The ratio is flat, as 1 funds sold all VolitionRX Ltd shares owned while 1 reduced positions. only 2 funds bought stakes while 5 increased positions. They now own 6.13 million shares or 0.84% more from 6.08 million shares in 2016Q1.
Moreover, Southpoint Cap Advsr L P has 0.13% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 800,000 shares. The Kansas-based Creative Planning has invested 0% in VolitionRX Ltd (NYSEMKT:VNRX). Blackrock Fund Advsrs holds 2,349 shares or 0% of its portfolio. Blackrock, a New York-based fund reported 1,000 shares. Lagoda Mgmt Limited Partnership has 1.62 million shares for 1.9% of their US portfolio. National Asset holds 0.01% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX) for 12,000 shares. Geode Cap Mngmt Ltd Liability accumulated 63,662 shares or 0% of the stock. Goldman Sachs Grp holds 19,388 shares or 0% of its portfolio. Garrison Bradford And accumulated 15,500 shares or 0.05% of the stock. Fincl Bank Of America De, a North Carolina-based fund reported 1 shares. Knoll Capital Mngmt Lp last reported 461,538 shares in the company. Morgan Stanley, a New York-based fund reported 51,900 shares. Moreover, Tower Rech Capital Ltd Com (Trc) has 0% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 659 shares. Blackrock Advsr Ltd Llc holds 0% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX) for 1,424 shares. National Bank Of New York Mellon Corp accumulated 0% or 10,355 shares.
More recent VolitionRX Ltd (NYSEMKT:VNRX) news were published by: Quotes.Wsj.com which released: “VolitionRX Ltd. VNRX (US: NYSE MKT)” on May 24, 2014. Also Marketwatch.com published the news titled: “VolitionRX Ltd. NYSE MKT: VNRX” on October 31, 2011. Seekingalpha.com‘s news article titled: “VolitionRx, Ltd.: Liquid Biopsy Cancer Screening Play” with publication date: March 24, 2016 was also an interesting one.
VNRX Company Profile
VolitionRx Limited, incorporated on September 24, 1998, is a clinical-stage life sciences company. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.